Dr. Ibrahim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
245 Terracina Blvd
Ste 206
Redlands, CA 92373Phone+1 909-793-4336Fax+1 909-793-3325
Summary
- Dr. Emad Ibrahim is an oncologist in Redlands, CA and is affiliated with multiple hospitals in the area, including Loma Linda University Medical Center and Redlands Community Hospital. He received his medical degree from University of Alexandria Faculty of Medicine and has been in practice 30 years. He also speaks multiple languages, including Arabic. He specializes in hematology and medical oncology and is experienced in immune thrombocytopenic purpura, myeloproliferative disorders, Hodgkin's and non Hodgkin's lymphoma, multiple myeloma, lung, breast, prostate and colon cancer. He has several publications and over 250 citing. He is a full clinical professor at University of California School of Medicine and associate Professor at Loma Linda University. He is the director of Redlands Community Hospital Cancer program and runs an active clinical trials program at his practice.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1994 - 1997
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1991 - 1994
University of Alexandria Faculty of MedicineClass of 1988
Certifications & Licensure
CA State Medical License 1992 - 2026
WA State Medical License 1993 - 1999- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2023 Jun 30
Roles: Contact
Publications & Presentations
PubMed
- 21 citationsEfficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical TrialDouglas W. Blayney, Qingyuan Zhang, Jifeng Feng, Yanqiu Zhao, Igor Bondarenko
JAMA Oncology. 2020-11-01 - 9 citationsAn open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.Jeffrey L. Vacirca, Arlene Chan, Klára Mezei, Clarence S. Adoo, Zsuzsanna Pápai
Cancer Medicine. 2018-05-01 - 376 citationsNeratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3...Miguel Martin, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy
The Lancet. Oncology. 2017-12-01
Professional Memberships
- Member
- Member
- Member
Other Languages
- Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
